Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 21, 2014; 20(47): 18001-18012
Published online Dec 21, 2014. doi: 10.3748/wjg.v20.i47.18001
Published online Dec 21, 2014. doi: 10.3748/wjg.v20.i47.18001
Figure 1 Flow diagram of the literature search and the study selection process.
GEM: Gemcitabine.
Figure 2 Forest plots of the effects of gemcitabine-based combination chemotherapy in patients with biliary tract cancer.
A: Disease response rate; B: Disease control rate; C: Progression-free survival; D: Overall survival. Gem: Gemcitabine monotherapy; Gem-based: Gem-based combination chemotherapy; non-Gem-based: non-Gemcitabine-based chemotherapy.
Figure 3 Forest plots of the main toxicities of gemcitabine-based combination chemotherapy in patients with biliary tract cancer.
A: Leukopenia; B: Anemia; C: Neutropenia; D: Thrombocytopenia; E: Increased alanine aminotransferase level. Gem: gemcitabine monotherapy; Gem-based: Gem-based combination chemotherapy; non-Gem-based: non-Gem-based chemotherapy.
Figure 4 Begg’s funnel plot for the assessment of publication bias.
- Citation: Liu H, Zhang QD, Li ZH, Zhang QQ, Lu LG. Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: A meta-analysis. World J Gastroenterol 2014; 20(47): 18001-18012
- URL: https://www.wjgnet.com/1007-9327/full/v20/i47/18001.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i47.18001